Go to main content

SGLT-2 Inhibitors

Can You Have DKA Without High Blood Sugars?

Discover the hidden risks of diabetic ketoacidosis (DKA) in insulin-treated diabetes. Learn about euglycemic DKA, triggered by SGLT-2 inhibitors.

Brenzavvy, a Type 2 Diabetes Drug, Available for Less Than $50 Month

New study in Diabetes, Obesity and Metabolism reveals Brenzavvy, an affordable SGLT-2 inhibitor for type 2 diabetes, is heart-safe and effective. It lowers blood sugar and A1C levels, reducing diabetes complications risk.

What Are SGLT-2 Inhibitors and How Can They Help Your Heart?

SGLT-2 inhibitors can protect your heart! This type of medicine is recommended for people with type 2 diabetes who have heart disease or risk factors related to heart disease. Learn about the use of these medicines, including side effects, their effect on A1C, and their role in supporting heart health

The Power of Fixed-Dose Combinations – What SGLT-2 and DPP-4 Inhibitors Can Do in a Single Pill

When one is better than two – how combining two effective diabetes drugs into a single pill can improve management.

FDA Approves New Once-Daily Pill for Type 2 Diabetes: Steglatro

Steglatro (ertugliflozin) approved on its own and as part of two different combination therapies. Launch in early 2018.

Novel Type 2 Diabetes Therapy Dapagliflozin Recommended for Approval in Europe